With Bristol Myers Squibb, Viz.ai intends to deploy an AI algorithm and a provider workflow software dubbed Viz HCM, to identify and triage patients who could need additional evaluation for the detection of the heart condition
Viz.ai signs a multi-year agreement with Bristol Myers Squibb to enable earlier detection of HCM. (Credit: Jonathan Schilling/Wikipedia.org)
Viz.ai, an artificial intelligence (AI) powered disease detection and care coordination platform, has forged a multi-year agreement with Bristol Myers Squibb to enable earlier detection and management of suspected hypertrophic cardiomyopathy (HCM).
With Bristol Myers Squibb, Viz.ai intends to deploy an AI algorithm and a provider workflow software dubbed Viz HCM, to identify and triage patients who may need additional assessment for the detection of the heart condition.
Viz.ai has filed a de novo request to the US Food and Drug Administration (FDA) for the algorithm as a software-as-a-medical-device (SaMD).
The request has been accepted by the US authority for review, said the AI disease detection firm.
The Viz HCM software is designed to automatically evaluate routine electrocardiograms (ECGs) from across a health system, identify probable cases of HCM, and inform the appropriate cardiologist.
The physician can then examine the ECG in a timely manner and take the necessary clinical action, such as prescribing follow-up diagnostic tests in addition to the standard of care.
Viz.ai CEO Chris Mansi said: “Hypertrophic cardiomyopathy can be a devastating disease. The agreement with Bristol Myers Squibb gives us the opportunity to enable underdiagnosed and underserved HCM patients to get the care they need from appropriate providers at the right time.
“Incorporating the new HCM module into the Viz Cardio Suite is expected to enhance detection, expedite care, and empower clinicians and patients.”
Viz HCM will be combined into the Viz.ai cardio suite for US hospitals.
Through the integration, it is anticipated to advance cardiac care coordination through a mobile-based ECG viewer equipped with timely AI-powered alerts and communication tools.
Bristol Myers Squibb vice president and digital health product management head Suhas Krishna said: “We are excited to continue building momentum in our support of Viz.ai’s research and development programme.
“The speed and quality in which this novel AI algorithm & workflow sequencing product was designed, verified, validated, and submitted by Viz.ai for agency review is testament to the ability to drive rapid and meaningful innovation in healthcare.”
Upon the receipt of FDA clearance, Viz.ai plans to launch Viz HCM broadly.